The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype

Pharmacogenetics and Genomics

Volumn 21, Issue 12, 2011, Pages 820-828

  Shon, Ji Hong ^a,b   Ku, Hei Young ^a   Bae, Seol Youn ^a,b   Oh, Min Kyung ^a,b   Yeo, Chang Woo ^a,b   Bae, Soo Kyung ^a,b   Shin, Jae Gook ^a,b  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

cytochrome P450 3A5; genetic polymorphism; oral disposition; phosphodiesterase type 5 inhibitor; sildenafil; udenafil; vardenafil

Indexed keywords

CYTOCHROME P450 3A5; SILDENAFIL; UDENAFIL; VARDENAFIL;

ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CROSSOVER PROCEDURE; GENOTYPE; HUMAN; INCUBATION TEMPERATURE; MAXIMUM PLASMA CONCENTRATION; MICROSOME; OPEN STUDY; PRIORITY JOURNAL;

EID: 81055157810     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834b79e6     Document Type: Article

References (41)

1. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000; 52:375-414.
2. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 56:453-459. (Pubitemid 34855305)
3. Sandner P, Hutter J, Tinel H, Ziegelbauer K, Bischoff E. PDE5 inhibitors beyond erectile dysfunction. Int J Impot Res 2007; 19:533-543. (Pubitemid 350059687)
4. Carson CC 3rd. Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. Curr Urol Rep 2003; 4:488-496.
5. Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42:1855-1860. (Pubitemid 37433669)
6. Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and bloodpressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83:21C-28C. (Pubitemid 29122754)
7. Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR, et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol 2008; 65:848-854. (Pubitemid 351677425)
8. Mehrotra N, Gupta M, Kovar A, Meibohm B. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007; 19:253-264. (Pubitemid 46701452)
9. Klotz T, Sachse R, Heidrich A, Jockenhovel F, Rohde G,Wensing G, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001; 19:32-39. (Pubitemid 33777030)
10. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005; 45:987-1003. (Pubitemid 41192358)
11. Ji HY, Lee HW, Kim HH, Kim DS, Yoo M, Kim WB, et al. Role of human cytochrome P450 3A4 in the metabolism of DA-8159, a new erectogenic. Xenobiotica 2004; 34:973-982. (Pubitemid 40070100)
12. Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, et al. The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos 2008; 36:986-990. (Pubitemid 351717478)
13. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30:883-891. (Pubitemid 34815417)
14. Wrighton SA, Ring BJ, Watkins PB, VandenBranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989; 36:97-105. (Pubitemid 19191265)
15. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391. (Pubitemid 32268418)
16. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14:147-154. (Pubitemid 38373108)
17. Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 2006; 80:646-656. (Pubitemid 44920220)
18. Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007; 47:87-93.
19. Park JY, Kim KA, Park PW, Lee OJ, Kang DK, Shon JH, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 2006; 79:590-599.
20. Garsa AA, McLeod HL, Marsh S. CYP3A4and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet 2005; 6:19.
21. Bae SK, Kang MJ, Yeo CW, Kim MJ, Shon JH, Liu KH, et al. Simultaneous determination of udenafil and its active metabolite, DA-8164, in human plasma and urine using ultra-performance liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Biomed Chromatogr 2008; 22:939-946.
22. Kim J, Ji H, Kim SJ, Lee HW, Lee SS, Kim DS, et al. Simultaneous determination of sildenafil and its active metabolite UK-103,320 in human plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2003; 32:317-322. (Pubitemid 36588732)
23. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002; 34:83-448. (Pubitemid 34311090)
24. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB. The human CYP3A subfamily: practical considerations. Drug Metab Rev 2000; 32:339-361. (Pubitemid 32001911)
25. Lee SJ, Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 2005; 6:357-371. (Pubitemid 40916359)
26. Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, et al. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol 2003; 66:2333-2340. (Pubitemid 37456741)
27. Milligan PA, Marshall SF, Karlsson MO. A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol 2002; 53 (Suppl 1):45S-52S.
28. Troconiz IF, Tillmann C, Staab A, Rapado J, Forgue ST. Tadalafil population pharmacokinetics in patients with erectile dysfunction. Eur J Clin Pharmacol 2007; 63:583-590. (Pubitemid 46684493)
29. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-1294. (Pubitemid 35284253)
30. Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, et al. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/Pglycoprotein transporter. PLoS One 2011; 6:e19329.
31. Ufer M, Dilger K, Leschhorn L, Daufresne L, Mosyagin I, Rosenstiel P, et al. Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin Pharmacol Ther 2008; 84:43-46. (Pubitemid 351861497)
32. Hustert E, Haberl M, Burk O,Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11:773-779. (Pubitemid 33151512)
33. Balram C, Zhou Q, Cheung YB, Lee EJ. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 2003; 59:123-126. (Pubitemid 36793724)
34. Roy JN, Lajoie J, Zijenah LS, Barama A, Poirier C,Ward BJ, et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 2005; 33:884-887. (Pubitemid 41002766)
35. Park PW, Seo YH, Ahn JY, Kim KA, Park JY. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther 2009; 34:569-574.
36. CIALISs(tadalafil) prescribing information. Available at: http://pi.lilly.com/us/cialis-pi.pdf. 2010. [Accessed 10 July 2011].
37. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338:1397-1404. (Pubitemid 28221980)
38. CDER/FDA. Viagra(Sildenafil) Joint Clinical Review NDA-20-895 Clinical pharmacology and biopharmaceutics. 1998. pp. 21-22. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/NDA/98/viagra/TABLE-OF-CONTENTS. PDF.
39. VIAGRAs(sildenafil citrate) prescribing information, 2007. Available at: http://www.pfizer.com/files/products/uspi-viagra.pdf. [Accessed 1 March 2011].
40. LEVITRAs(Vardenafil HCl) prescribing information, 2008. Available at: http://www.univgraph.com/bayer/inserts/levitra.pdf. [Accessed 1 March 2011].
41. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004; 110:3149-3155. (Pubitemid 39492012)